Your browser doesn't support javascript.
loading
Heterogenous transmission and seroprevalence of SARS-CoV-2 in two demographically diverse populations with low vaccination uptake in Kenya, March and June 2021.
Munywoki, Patrick K; Bigogo, Godfrey; Nasimiyu, Carolyne; Ouma, Alice; Aol, George; Oduor, Clifford O; Rono, Samuel; Auko, Joshua; Agogo, George O; Njoroge, Ruth; Oketch, Dismas; Odhiambo, Dennis; Odeyo, Victor W; Kikwai, Gilbert; Onyango, Clayton; Juma, Bonventure; Hunsperger, Elizabeth; Lidechi, Shirley; Ochieng, Caroline Apondi; Lo, Terrence Q; Munyua, Peninah; Herman-Roloff, Amy.
Afiliación
  • Munywoki PK; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Bigogo G; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Nasimiyu C; Global Health Program, Washington State University - Global Health Kenya (WSU-GH Kenya), Nairobi, Kenya.
  • Ouma A; Paul G. Allen School of Global Health, Washington State University, Pullman, Washington, USA.
  • Aol G; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Oduor CO; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Rono S; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
  • Auko J; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
  • Agogo GO; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Njoroge R; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Oketch D; Global Health Program, Washington State University - Global Health Kenya (WSU-GH Kenya), Nairobi, Kenya.
  • Odhiambo D; Global Health Program, Washington State University - Global Health Kenya (WSU-GH Kenya), Nairobi, Kenya.
  • Odeyo VW; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Kikwai G; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Onyango C; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
  • Juma B; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Hunsperger E; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Lidechi S; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Ochieng CA; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.
  • Lo TQ; Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
  • Munyua P; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
  • Herman-Roloff A; Division for Global Health Protection, Global Health Center, U.S. Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.
Gates Open Res ; 7: 101, 2023.
Article en En | MEDLINE | ID: mdl-37990692
ABSTRACT

Background:

SARS-CoV-2 has extensively spread in cities and rural communities, and studies are needed to quantify exposure in the population. We report seroprevalence of SARS-CoV-2 in two well-characterized populations in Kenya at two time points. These data inform the design and delivery of public health mitigation measures.

Methods:

Leveraging on existing population based infectious disease surveillance (PBIDS) in two demographically diverse settings, a rural site in western Kenya in Asembo, Siaya County, and an urban informal settlement in Kibera, Nairobi County, we set up a longitudinal cohort of randomly selected households with serial sampling of all consenting household members in March and June/July 2021. Both sites included 1,794 and 1,638 participants in the March and June/July 2021, respectively. Individual seroprevalence of SARS-CoV-2 antibodies was expressed as a percentage of the seropositive among the individuals tested, accounting for household clustering and weighted by the PBIDS age and sex distribution.

Results:

Overall weighted individual seroprevalence increased from 56.2% (95%CI 52.1, 60.2%) in March 2021 to 63.9% (95%CI 59.5, 68.0%) in June 2021 in Kibera. For Asembo, the seroprevalence almost doubled from 26.0% (95%CI 22.4, 30.0%) in March 2021 to 48.7% (95%CI 44.3, 53.2%) in July 2021. Seroprevalence was highly heterogeneous by age and geography in these populations-higher seroprevalence was observed in the urban informal settlement (compared to the rural setting), and children aged <10 years had the lowest seroprevalence in both sites. Only 1.2% and 1.6% of the study participants reported receipt of at least one dose of the COVID-19 vaccine by the second round of serosurvey-none by the first round.

Conclusions:

In these two populations, SARS-CoV-2 seroprevalence increased in the first 16 months of the COVID-19 pandemic in Kenya. It is important to prioritize additional mitigation measures, such as vaccine distribution, in crowded and low socioeconomic settings.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gates Open Res Año: 2023 Tipo del documento: Article País de afiliación: Kenia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gates Open Res Año: 2023 Tipo del documento: Article País de afiliación: Kenia